Catalyst
Slingshot members are tracking this event:
Phase 1/2 data of Sarepta's (SRPT) MYO-101 in Duchenne muscular dystrophy - LGMD2E due February 27, 2019
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SRPT | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 27, 2018
Occurred Source:
http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-positive-and-robust-expression
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Myo-101, Duchenne Muscular Dystrophy, Lgmd2e, Phase 1/2 Data
